Lichen planus hair loss, most commonly presenting as lichen planopilaris (LPP) or frontal fibrosing alopecia (FFA), is a chronic inflammatory condition that causes permanent, scarring hair loss by destroying the hair follicle. Unlike temporary forms of alopecia, the follicular damage caused by LPP is irreversible, making early diagnosis and prompt treatment essential. This article explains how lichen planus affects the scalp, how to recognise the symptoms, what to expect from diagnosis and NHS treatment, and when to seek further medical advice.

How Lichen Planus Affects the Scalp and Hair Follicles

Lichen planopilaris causes irreversible scarring alopecia through T-lymphocyte-mediated destruction of follicular stem cells, replacing follicles with fibrous scar tissue and eliminating any capacity for regrowth.

Lichen planus is a chronic inflammatory condition that can affect the skin, mucous membranes, nails, and scalp. When it involves the scalp specifically, it is referred to as lichen planopilaris (LPP) — a form of primary cicatricial (scarring) alopecia. Unlike non-scarring hair loss conditions such as alopecia areata or telogen effluvium, lichen planus hair loss results from irreversible destruction of the hair follicle itself.

Not sure if this is normal? Chat with one of our pharmacists →

The underlying mechanism is thought to involve a T-lymphocyte-mediated immune attack directed at the hair follicle epithelium, particularly targeting the follicular stem cells located in the bulge region. The condition is widely considered to be immune-mediated and is likely autoimmune in nature, though the precise trigger has not been fully established. Once the stem cells are destroyed, the follicle loses its capacity to regenerate, and the affected area is replaced by fibrous scar tissue. This is why early diagnosis and prompt treatment are so important — the window for preserving follicular function is limited.

Lichen planopilaris can occur in isolation or alongside cutaneous lichen planus elsewhere on the body. A related variant, known as frontal fibrosing alopecia (FFA), predominantly affects the frontal hairline and eyebrows and is classified by many dermatologists as a subtype of LPP, though this remains a convention rather than a fully settled distinction. Both conditions share similar pathological features and are increasingly recognised within NHS dermatology services. Understanding the follicular destruction process helps explain why treatment focuses primarily on halting progression rather than reversing existing hair loss.

Further information on LPP and FFA is available from the British Association of Dermatologists (BAD) patient information leaflets and the Primary Care Dermatology Society (PCDS).

Recognising the Symptoms of Lichen Planopilaris

Key symptoms include scalp itching, burning, perifollicular redness and scaling, and patchy hair loss; absence of follicular openings on dermoscopy is a distinguishing feature of scarring alopecia.

The symptoms of lichen planopilaris can be subtle in the early stages, which often leads to a delay in diagnosis. Patients typically report a combination of scalp symptoms and visible changes to the hair and hairline. Being aware of the key signs can help prompt earlier medical review.

Common symptoms include:

• Scalp itching, burning, or tenderness — often described as a stinging or painful sensation

• Redness and scaling around individual hair follicles (perifollicular erythema and scale)

• Patchy hair loss, often in irregular or multifocal areas across the scalp

• A progressive recession of the frontal or temporal hairline (particularly in frontal fibrosing alopecia)

• Loss of eyebrows, eyelashes, or body hair — this is more commonly associated with FFA than with classic LPP

• A smooth, pale, or shiny appearance to areas of established scarring

One distinguishing feature of LPP compared with non-scarring alopecia is the absence of follicular openings (ostia) in affected areas. This is typically confirmed by dermoscopy (trichoscopy) during a clinic examination rather than being apparent to patients themselves. In active disease, perifollicular scale and redness are visible at the margins of hair loss patches.

It is worth noting that some individuals experience minimal or no symptoms despite active inflammation, making self-monitoring difficult. Symptoms may also fluctuate, with periods of relative stability followed by flares. If you notice progressive hair thinning accompanied by scalp discomfort or redness around the follicles, it is advisable to seek a medical opinion promptly rather than waiting to see if the condition resolves on its own.

Getting a Diagnosis: What to Expect from Your GP or Dermatologist

Diagnosis requires specialist referral; a scalp punch biopsy is the gold standard, supported by dermoscopy and blood tests to exclude other causes, alongside a thorough drug history to rule out lichenoid drug reactions.

Diagnosing lichen planus hair loss requires a careful clinical assessment, and in most cases a referral to a dermatologist is necessary for confirmation. Your GP will typically begin by taking a detailed history of your symptoms, including the duration and pattern of hair loss, any associated scalp symptoms, and whether you have a personal or family history of autoimmune or inflammatory conditions.

Your GP may examine the scalp and refer you to secondary care if LPP or another form of scarring alopecia is suspected. UK primary care guidance from the PCDS and BAD recommends prompt specialist referral when scarring alopecia is a possibility, as early intervention is important to limit irreversible follicular damage. Within dermatology, the following investigations may be undertaken:

• Dermoscopy (trichoscopy): A handheld magnifying tool used to examine the scalp surface and follicular architecture in detail, helping to identify perifollicular scale, loss of follicular openings, and other LPP-specific features

• Scalp biopsy: The gold standard for confirming a diagnosis of LPP; a small tissue sample (typically a 4 mm punch biopsy) is taken under local anaesthetic from an active margin of hair loss and examined histologically for the characteristic lichenoid infiltrate around the follicle

• Blood tests: These may be performed to help exclude other causes of hair loss, such as thyroid dysfunction, iron deficiency, or lupus erythematosus; they do not confirm a diagnosis of LPP but are a useful part of the overall assessment

It is important to be honest with your dermatologist about all medications you are taking. Certain drugs — including some antihypertensives (such as ACE inhibitors, thiazide diuretics, and beta-blockers), NSAIDs, gold salts, and some antimalarials — can cause lichenoid reactions that may mimic LPP clinically and histologically. Drug-induced lichenoid reactions are distinct from idiopathic LPP or FFA, and identifying a causative drug may alter management. A thorough drug history helps ensure an accurate diagnosis and appropriate management plan.

Treatment Options Available on the NHS

NHS treatment focuses on halting inflammation using off-label agents including topical or intralesional corticosteroids, hydroxychloroquine, and systemic immunosuppressants, all requiring specialist monitoring for side effects.

Experiencing these side effects? Our pharmacists can help you navigate them →

There is currently no cure for lichen planopilaris, and the primary goal of treatment is to suppress the inflammatory process and halt further hair loss. Because scarring is irreversible, early intervention offers the best chance of preserving existing hair. Treatment is typically managed by a consultant dermatologist and tailored to the severity and activity of the disease.

It is important to be aware that most treatments used for LPP and FFA are prescribed off-label — that is, they are not specifically licensed for these conditions. Their use is based on clinical evidence, specialist experience, and shared decision-making between you and your dermatologist.

First-line treatments commonly used on the NHS include:

• Topical corticosteroids: High-potency preparations such as clobetasol propionate are applied directly to affected areas to reduce localised inflammation

• Intralesional corticosteroid injections: Triamcinolone acetonide injected into the scalp can be effective for active, symptomatic patches and is often administered in outpatient dermatology clinics

• Hydroxychloroquine: An antimalarial agent with immunomodulatory properties, widely used as a systemic treatment for LPP. The dose should not exceed 5 mg/kg of actual body weight per day to minimise the risk of retinal toxicity. A baseline ophthalmological assessment is recommended before starting treatment, with annual eye screening from year five onwards (or earlier if risk factors such as renal impairment are present), in line with Royal College of Ophthalmologists (RCOphth) guidance. Patients should report any visual disturbances promptly

• Tetracycline antibiotics (e.g., doxycycline): Used for their anti-inflammatory rather than antimicrobial properties in some patients. Common cautions include photosensitivity, gastrointestinal irritation (take with food and water; remain upright for at least 30 minutes), and avoidance in pregnancy

• 5-alpha-reductase inhibitors (e.g., finasteride or dutasteride): These are used off-label in the management of FFA and are among the more commonly prescribed systemic options in UK specialist practice. Women of childbearing potential must use effective contraception during treatment, as these medicines are teratogenic and must not be used during pregnancy

For more refractory cases, dermatologists may consider second-line agents, including:

• Mycophenolate mofetil: Requires regular monitoring of full blood count, liver function, and renal function. It is teratogenic; women of childbearing potential must comply with the MHRA Mycophenolate Pregnancy Prevention Programme, which requires two forms of effective contraception and regular pregnancy testing

• Ciclosporin: Requires monitoring of blood pressure and renal function, and careful review of potential drug interactions

• Pioglitazone: Has shown some promise in small studies for LPP but should be considered experimental and is used off-label only. The MHRA has highlighted risks associated with pioglitazone, including heart failure, fluid retention, bone fractures, and a possible signal for bladder cancer; it should only be considered in selected refractory cases after careful individual risk–benefit assessment

All systemic treatments carry potential side effects and require monitoring in line with NHS prescribing guidelines. Prescribing decisions are made on an individual risk-benefit basis in secondary care.

If you experience any suspected side effects from your treatment, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This applies to all medicines, including those prescribed off-label.

Managing Hair Loss and Supporting Regrowth

Regrowth in scarred areas is not possible, but controlling active inflammation can prevent further loss; practical support includes gentle scalp care, camouflage options, psychological support, and correcting nutritional deficiencies.

Because lichen planus hair loss involves permanent follicular scarring in established areas, regrowth of hair in those zones is generally not possible. However, where treatment successfully controls active inflammation at the margins of hair loss, further progression can be slowed or halted, and some patients do experience partial regrowth in areas where follicles have not yet been fully destroyed.

Beyond medical treatment, there are several practical strategies that can help manage the impact of hair loss:

• Scalp care: Using gentle, fragrance-free shampoos and avoiding harsh chemical treatments or heat styling can help reduce scalp irritation and support overall scalp health

• Camouflage techniques: Hair fibres, scalp micropigmentation, and specialist wigs or hairpieces may help manage the cosmetic impact of hair loss. NHS wig provision is available in some circumstances, but eligibility criteria and whether charges apply vary between NHS Integrated Care Boards and Trusts; your dermatology team or local service can advise on what is available to you. Scalp micropigmentation and hair transplantation are best considered only when the disease has been inactive for a sustained period and after specialist advice, as active inflammation may affect outcomes

• Psychological support: Hair loss can have a significant effect on self-esteem and mental wellbeing. Referral to a clinical psychologist or support through organisations such as Alopecia UK may be beneficial

• Sun protection: For patients with frontal fibrosing alopecia, applying a broad-spectrum sunscreen to the exposed forehead and hairline is a reasonable general measure to protect against sunburn. Whether UV exposure or leave-on cosmetic products act as disease triggers remains an area of ongoing research, and no firm conclusions can currently be drawn; patients should discuss this with their dermatologist

It is also worth maintaining a healthy, balanced diet. Nutritional deficiencies — particularly in iron, zinc, and protein — can compound hair loss, even if they are not the primary cause. Supplements should be used to correct proven deficiencies rather than as a general measure; evidence for benefit beyond correcting a deficiency is limited. Your GP can arrange blood tests to check for any correctable deficiencies.

When to Seek Further Medical Advice

Seek prompt review if hair loss accelerates, scalp symptoms worsen, signs of infection appear, or medication side effects develop — particularly visual disturbances with hydroxychloroquine or systemic symptoms on immunosuppressants.

Knowing when to escalate your concerns is an important part of managing lichen planus hair loss safely and effectively. Because LPP is a progressive condition, timely review can make a meaningful difference to long-term outcomes.

You should contact your GP or dermatologist promptly if you notice:

• A sudden increase in the rate of hair shedding or a rapidly expanding area of hair loss

• New or worsening scalp symptoms such as pain, burning, or intense itching that are not controlled by current treatment

• Signs of skin infection on the scalp, including increased redness, warmth, swelling, or discharge

• Side effects from prescribed medications — for example, any visual disturbances if you are taking hydroxychloroquine (seek urgent review), or gastrointestinal symptoms with systemic treatments

• Fever, sore throat, or other signs of serious infection if you are taking an immunosuppressant such as mycophenolate or ciclosporin — seek urgent medical advice via your GP, NHS 111, or emergency services as appropriate

• Hair loss spreading to new areas, including the eyebrows, eyelashes, or body

If you have been stable on treatment but experience a flare, do not discontinue prescribed medication without medical advice, as this may worsen inflammation. Instead, contact your dermatology team for guidance on adjusting your management plan.

If you experience any suspected side effect from a prescribed medicine, please report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

For those who have exhausted standard NHS treatment options, referral to a specialist hair disorder clinic or a tertiary centre with expertise in scarring alopecia may be appropriate. Participation in clinical trials is another avenue worth discussing with your dermatologist, as research into LPP and FFA is ongoing; the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) can help you find relevant UK studies. Organisations such as the British Association of Dermatologists (BAD) and Alopecia UK can provide further information and signpost patients to appropriate support services.

Frequently Asked Questions